Published Online
on April 21, 2008

A more recent version of this article appeared on May 6, 2008

This Article Free upon publication Full Text (PDF) All Versions of this Article: 117/18/2407    most recent CIRCULATIONAHA.107.189473v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Vetter, V. L. Articles by Webb, C. L. PubMed PubMed Citation Articles by Vetter, V. L. Articles by Webb, C. L. Related Collections Other Ethics and Policy Arrhythmias, clinical electrophysiology, drugs Cerebrovascular disease/stroke Electrocardiology Cardiovascular Pharmacology

Submitted on ,
Accepted on ,

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing

Victoria L. Vetter MD, FAHA, Chair, Josephine Elia MD, Christopher Erickson MD, Stuart Berger MD, FAHA, Nathan Blum MD, Karen Uzark RN, PhD, FAHA, and Catherine L. Webb MD, FAHA

Key words: AHA Scientific Statements • attention deficit disorder with hyperactivity • cardiovascular monitoring • congenital heart disease • stimulant drugs • death, sudden • heart arrest • pediatrics